Leiomyosarcoma - 29 Studies Found
| Active, not recruiting |
: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma : Advanced or Metastatic Liposarcoma or Leiomyosarcoma : 2012-08-06 :
|
| Completed |
: Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma :
: 2006-01-24 : Drug: gemcitabine, docetaxel, doxorubicin Cycles = 28 days |
| Active, not recruiting |
: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma :
: 2006-12-19 : Drug: Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks. |
| Completed |
: Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus :
: 2006-09-19 : Drug: sunitinib malate Given orally Other Names: |
| Completed |
: Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus :
|
| Active, not recruiting |
: Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy :
|
| Recruiting |
: Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery :
: |
| Completed |
: Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus :
: 2008-01-31 : Drug: Docetaxel plus Gemcitabine Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV |
| Not yet recruiting |
: Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery :
: 2017-03-01 :
|
| Completed |
: Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus :
|